IRLAB’s drug candidate mesdopetam’s mechanism of action receives confirmation by independent scientists

March 25, 2021

IRLAB (Nasdaq Stockholm: IRLAB A) announced today that independent scientists have confirmed that the dopamine D3 receptor (D3R) is a highly promising drug target with therapeutic potential in levodopa-induced dyskinesia, especially when the receptor’s unique signaling properties are taken into account. IRLAB’s mesdopetam is currently the most advanced D3R antagonist compound in the global neurology pipeline. It is used in the scientific article to exemplify a compound that could have an impact on the management of anumber of disorders marked by aberrant D3R activity. The article was published in the scientific journal Biomedicines in March 2021.

IRLAB (Nasdaq Stockholm: IRLAB A) announced today that independent scientists have confirmed that the dopamine D3 receptor (D3R) is a highly promising drug target with therapeutic potential in levodopa-induced dyskinesia, especially when the receptor’s unique signaling properties are taken into account. IRLAB’s mesdopetam is currently the most advanced D3R antagonist compound in the global neurology pipeline. It is used in the scientific article to exemplify a compound that could have an impact on the management of anumber of disorders marked by aberrant D3R activity. The article was published in the scientific journal Biomedicines in March 2021.

“The authors of this scientific article use mesdopetam as the example of a new promising drug candidate targeting the D3R,” says Nicholas Waters, CEO at IRLAB. “It is great to see that mesdopetam and our science raised such interest, highlighting mesdopetam’s unique mechanism of action targeting the D3R. The discovery of mesdopetam and its novel mechanism illustrates the effectiveness of ISP, our systems biology research platform.”

Mesdopetam, a first-in-class compound, is in development for the treatment of levodopa-induced dyskinesias in Parkinson’s disease (PD-LIDs) and psychoses in Parkinson’s disease (PD-P). An international Phase IIb/III PD-LIDs study is currently ongoing. The wider potential for mesdopetam within neurological indications includes prevention of PD-LIDs and treatment of and tardive dyskinesias (TD). Tardive dyskinesia is a complication in patients chronically exposed to antipsychotics and is associated with upregulated D3R in the brain; More than 3 million patients are affected worldwide, and an unmet clinical need exists.

The publication: Lanza, K.; Bishop, C. Dopamine D3 Receptor Plasticity in Parkinson’s Disease and L-DOPA-Induced Dyskinesia. Biomedicines 2021, 9, 314. https://doi.org/10.3390/biomedicines9030314.

Documents & Links